Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Edesa Biotech, Inc.NASDAQ: EDSA
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q2 FY2026 research & development of $2.77M rose 471.4% year over year, ahead of the +141.7% change in trailing-twelve-month research & development. Sequentially, it rose 146.0% from the prior quarter. Over 3 fiscal years it compounded at -35.0% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +471.4% holds above the trailing-twelve-month pace of +141.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.67M USD
- Year-over-year change
- +27.3%
- 4-year CAGR
- -32.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 3.67M | +27.3% |
| FY2024 | 2024-09-30 | 2.88M | -39.9% |
| FY2023 | 2023-09-30 | 4.79M | -64.0% |
| FY2022 | 2022-09-30 | 13.34M | -25.7% |
| FY2021 | 2021-09-30 | 17.95M | — |
Research & Development vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 research & development of $6.06M is the lowest of the 2 companies compared; the peer median is $22.1M.
- Its year-over-year change of +141.7% is the lowest of 2, against a peer median of +292.9%.
- Over three fiscal years its annual growth of -35.0% compares with a peer median of +39.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.1M | +292.9% | +39.4% | — | |
| LTM Mar 2026 | $6.06M | +141.7% | -35.0% | — | |
| Peer median (excluding EDSA) | $22.1M | +292.9% | +39.4% | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Gross Profit | (118.79K) | (118.19K) | (183.47K) | (186.05K) | (119.27K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M |
| Selling, General & Admin | 5.73M | 5.04M | 4.43M | 4.13M | 4.24M |
| Operating Expenses | 23.68M | 18.37M | 9.22M | 7.01M | 7.79M |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| EBITDA | (13.22M) | (17.43M) | (8.19M) | (5.98M) | (7.07M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.68M) | (18.37M) | (9.22M) | (7.01M) | (7.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 11.17K | 64 | 289.85K | 153.5K | 2.56K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 10.34M | 822.67K | 849.14K | 845.5K | 726.84K |
| Income Before Tax | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.18M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 800 | 800 | 800 | 800 | 800 |
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.74) | (8.37) | (2.93) | (1.93) | (1.27) |
| EPS (Diluted) | (7.73) | (8.37) | (2.93) | (1.93) | (1.27) |
| Weighted Avg Shares | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
| Weighted Avg Shares (Diluted) | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.